Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 7, 2013; 19(21): 3199-3206
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3199
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3199
Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Qing-Lei Zeng, Fu-Sheng Wang, The Institute of Translational Hepatology, Beijing 302 Hospital, Peking University, Beijing 100039, China
Ji-Yuan Zhang, Zheng Zhang, Li-Feng Wang, Research Center for Biological Therapy, Beijing 302 Hospital, Beijing 100039, China
Author contributions: Zeng QL and Zhang JY contributed equally to this work; Zeng QL and Zhang JY contributed to the study idea, study design, literature search, manuscript writing and final revision of the article; Zhang Z and Wang LF contributed to the manuscript writing and the final revision of the article; Wang FS contributed to the study design, manuscript writing and the final revision of the article.
Supported by Grants from the National Key Basic Research Program of China, No. 2009CB522507, No. 2012CB519005; and Beijing Nova Program of China, No. Z12110702512071
Correspondence to: Fu-Sheng Wang, MD, PhD, The Institute of Translational Hepatology, Beijing 302 Hospital, Peking University, 100 Xisihuan Middle Road, Beijing 100039, China. fswang302@163.com
Telephone: +86-10-66933332 Fax: +86-10-66933332
Received: February 20, 2013
Revised: March 31, 2013
Accepted: April 17, 2013
Published online: June 7, 2013
Revised: March 31, 2013
Accepted: April 17, 2013
Published online: June 7, 2013
Core Tip
Core tip: We are entering an era in which the development of antiviral agents and successful treatment of chronic hepatitis C is rapidly escalating. In this review, we have summarized the history of anti-hepatitis C virus (HCV) agents from interferon-α (IFN-α) to the latest sofosbuvir- and ABT-450-based therapies. Although a new generation of direct acting anti-HCV agents has largely improved the sustained virologic response rates of patients, many unmet needs and questions remain, such as IFN-free regimens for difficult to treat patients, avoidance of cross-resistance, the role of interleukin-28B status as well as the management of some advanced and co-infected patients.